Mechanisms and management of bone pain

Cancer

Volumn 80, Issue 8 SUPPL., 1997, Pages 1608-1613

  Payne, Richard ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; CODEINE; DICLOFENAC; DIFLUNISAL; ETODOLAC; FENTANYL; FENTANYL CITRATE; FLURBIPROFEN; HYDROCODONE; HYDROCODONE BITARTRATE PLUS PARACETAMOL; HYDROMORPHONE; IBUPROFEN; KETOPROFEN; KETOROLAC TROMETAMOL; LEVORPHANOL; METHADONE; MORPHINE SULFATE; NABUMETONE; NAPROXEN; NARCOTIC ANALGESIC AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; ORAMORPH SR; OXYCODONE; PAMIDRONIC ACID; PARACETAMOL; PERCOCET; PERCODAN; PIROXICAM; SULINDAC; TRAMADOL; TRICYCLIC ANTIDEPRESSANT AGENT; TYLOX; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANALGESIA; BONE PAIN; CANCER PAIN; CHRONIC PAIN; CONFERENCE PAPER; DRUG EFFICACY; HUMAN; INTRAMUSCULAR DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; NAUSEA; NOCICEPTION; ORAL DRUG ADMINISTRATION; PAIN ASSESSMENT; PRIORITY JOURNAL; SUSTAINED RELEASE PREPARATION;

EID: 0030753267     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(sici)1097-0142(19971015)80:8+<1608::aid-cncr11>3.0.co;2-3     Document Type: Conference Paper

References (42)

1. Carr DB, Chapman CR, et al. Acute pain management: Operative or medical procedures and trauma - clinical practice guidelines. Rockville, MD: U.S. Department of Health and Human Services. 1992, pp. 1-145.
2. Jacox A, Carr DB, Payne R, et al. Clinical practice guidelines (No. 9): management of cancer pain. Rockville, MD: Agency for Health Care Policy and Research, 1994.
3. Foley KM. Pain. In: Cecil Textbook of Medicine. Bennett JC, Plum F, eds. Philadelphia: W. B. Saunders, 1996, pp. 100-7.
4. Cleeland CS, Gonin R, Hatfiled AK, Edmonson JH, Blum RH, Stewart JA, Pandya KJ. Pain and its treatment in outpatients with metastatic cancer. N Eng J Med 1994;330:592-6.
5. Portenoy RK, Kanner R, Foley KM. Pain Syndromes with Cancer. Philadelphia: 1996, P. 191-215.
6. Willis WD. The Neural Basis of Nociceptive Transmission in the Mammalian Nervous System. In: The Pain System. Basel, Germany: S. Karger, 1985.
7. Fields HL. Pain. New York: McGraw-Hill Book Company, 1987.
8. Payne R, Gonzales GS. Pathophysiology of pain in cancer and other terminal illnesses. In: Oxford Textbook of Palliative Medicine (In press) 1997.
9. Hagbarth KE. Exteroceptive, proprioceptive, and sympathetic activity recorded with microelectrodes from human peripheral nerves. Mayo Clin Proc 1979;54:353-65.
10. Torebjork HE, Schady W, Ochoa J. Sensory correlates of somatic afferent fiber activation. Hum Neurobiol 1984;3(1):15-20.
11. Meyer RA, Campbell JN. Myelinated nociceptive afferents account for the hyperalgesia that follows a burn to the hand. Science 1981;213:1527-9.
12. Roberts WJ. A hypothesis on the physiological basis for causalgia and related pains. Pain 1986;24(3):297-311.
13. Watkins LR, Maier SF, Goehler LE. Immune activation: the role of pro-inflammatory cytokines in inflammation, illness responses and pathological pain states. Pain 1995;63:289-302.
14. Schmidt RF, Schaible H-G, Messlinger K, Heppelmann B, Hanesch U, Pawlak M. Silent and Active Nociceptors: Structure, Functions, and Clinical Implications. Proceedings of the 7th World Congress on Pain, Progress in Pain Research and Management, Vol. 2, edited by Gebhart EG, Hammond DL, Jensen TS, eds., Seattle: IASP Press, 1994.
15. Arguello F, Cohen HJ. Structural and Microenvironmental Bone Marrow Factors Involved in the Pathogenesis of Bone Metastasis. In: Bone Metastasis-Mechanisms and Pathophysiology. Orr FW, Singh G, eds. New York: Chapman & Hall, 1996.
16. Blatch GL, Zetter BR. Bone marrow-derived growth factors for metastatic cancer cells. In: Bone metastasis-mechanisms and pathophysiology. Orr FW, Singh G, eds. New York: Chapman & Hall, 1996.
17. Sibinga NE, Goldstein A. Opioid peptides and opioid receptors in cells of the immune system. Ann Rev Immunol 1988;6:219-49.
18. Stein CM, Wood AJJ, Pincus T. Implementation of multiple outpatient formularies: undesirable effects. Ann Oncol 1997;61:1-7.
19. Stein C. The control of pain in peripheral tissue by opioids. N Engl J Med 1995;332(25):1685-90.
20. Visceral sensation. Cervero F, Morrison JFB. In: Progress in brain research; v. 67; New York: Elsevier Science Pub. Co., 1986.
21. Gebhart GF. Visceral polymodal receptors. Prog Brain Res 1996;113:101-12.
22. Casey KL. Pain and central nervous system disease: the central pain syndromes. New York: Raven Press, 1991.
23. Coggeshall RD. Afferent fibers in the ventral root. Neurosurgery 1979;4:443-38.
24. Cervero F, Iggo A. The substantia gelatinosa of the spinal cord. A critical review. Brain 1980;103:717-22.
25. Basbaum AI, Fields HL. Endogenous pain control mechanisms: Review and hypothesis. Ann Neurol 1978;4:451-462.
26. Fields HL, Besson JM, eds. Pain modulation: fMRI pain neuroimaging studies. Prog Brain Res 77, 1986.
27. Iadarola MJ, Max MB, Berman KF, Byas-Smith MG, Coghill RC, Gracely RH, et al.Unilateral decrease in thalamic activity observed with positron emission tomography in patients with chronic neuropathic pain. Pain 1995;63:55-64.
28. Rainville P, Duncan GH, Price DD, Carrier B, Bushnell MC. Pain affect encoded in human anterior cingulate but not somatosensory cortex. Science 1997;277:968-71.
29. Hammond DL. Control systems for nociceptive afferent processing: the descending inhibitory pathways. In: Yaksh TL (ed.), Spinal Afferent Processing. New York: Plenum Press, 1986, p 363-90.
30. Woolf CJ, Thompson SWN. The induction and maintenance of central sensitization is dependent on N-methyl-D-aspartic acid receptor activation; implications for the treatment of post-injury pain hypersensitivity states. Pain 1991;44:293-9.
31. Backonja M, Arndt G, Gombar KA, Check B, Zimmermann M. Response of chronic neuropathic pain syndromes to ketamine: a preliminary study [published erratum appears in Pain 1994 Sep; 58(3):433] Pain 1994;56:51-7.
32. Elliott KJ, Minami N, Kolesnikov YA, Pasternak GW, Inturrisi CE. The NMDA receptor antagonists, LY274614 and MK-801, and the nitric oxide synthase inhibitor, NG-nitro-L-agrinine, attenuate analgesic tolerance to the mu-opiod morphine but not to kappa opioids. Pain 1994;56(1):69-75.
33. Malmberg AB, Yaksh TL. Pharmacology of the spinal action of ketorolac, morphine, ST-91, U50488H, and L-PIA on the formalin test and an isobolographic analysis of the NSAID interaction. Anesthesialogy 1993;79:270-81.
34. Levy MH. Pharmacologic treatment of cancer pain. N Engl J Med 1996;335(15):1124-32.
35. Foley KM. Supportive care and quality of life. In: Cancer: principles & practice of oncology, Fifth edition. Eds: DeVita, VT, Hellman S, Rosenberg SA. Philadelphia: Lippincott-Raven Publishers, 1997.
36. Payne R, Weinstein SM, Hill CS Jr: The assessment and management of pain in the patient with cancer. In: Cancer in the nervous system. Levin V (ed): New York: Churchill Livingstone, 1995, p. 411-48.
37. Porter AT, McEwan AJB, Powe JE, Reid R, McGowan DG, Lukka H, Sathyanarayana JR, Yakemchuk VN, Thomas GM, Erlich LE, Crook J, Gulenchyn KY, Hong KE, Wesolowski C, Yardley J. Results of a randomized phase-III trial to evaluate the efficacy of strontium-89 adjuvant to local field external beam irradiation in the management of endocrine resistant metastatic prostate cancer, Int J Radiat Oncol Biol Phys 1993;25(5):805-13.
38. Tannock IF, Osoba D, Stockier MR, Ernst DS, Neville AJ, Moore MJ, et al. Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points. J Clin Oncol 1996;14(6):1756-64.
39. Hortobagjy GN. Efficacy of Pamidromate in Reducing Skeletal Complication in Patients with Breast Cancer and Lytic Bone Metastases. N Engl J Med 1996;335(24):1785-91.
40. Portenoy RK, Hagen NA. Breakthrough Pain: definition and management. Oncology (Special Supplement) 1898; Portenoy RK, Hagen NA. Breakthrough pain: definition, prevalence and characteristics. Pain 1990;41:273-81.
41. Portenoy RK, Hagen NA. Breakthrough Pain: definition and management. Oncology (Special Supplement) 1898; Portenoy RK, Hagen NA. Breakthrough pain: definition, prevalence and characteristics. Pain 1990;41:273-81.
42. Fine PG, Marcus M, DeBoer AJ, Van der Oord B. An open label study of oral transmucosal fentanyl citrate (OTFC) for the treatment of breakthrough cancer pain. Pain 1991; 45:149-53.